跳至主要内容
临床试验/IRCT20080901001165N53
IRCT20080901001165N53招募中3 期

Investigating the efficacy and safety of Interferon Beta1a nasal spray in controlling the symptoms of patients with COVID-19

Bagheiat-allah University of Medical Sciences0 个研究点目标入组 100 人开始时间: 待定最近更新:
适应症

试验速览

阶段
3 期
状态
招募中
发起方
入组人数
100

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 years 至 no limit(—)
性别
All

入选标准

  • Age: equal or more than 18 years;
  • The patient have written consciously and freely consent to participate in the study;
  • The patient's clinical symptoms (dry cough, shortness of breath, fever) confirm COVID-19.
  • Confirmed diagnosis of COVID-19, with either lung CT-Scan result, which is typical for COVID-19 pulmonary involvement,or RT-PCR confirmation.
  • Less than 7 days have passed since the onset of symptoms.

排除标准

  • History of allergy to this nasal spray ingredients;
  • Hypersensitivity reaction while taking this nasal spray;
  • The patient is in another clinical trial at the same time;
  • The patient needs to receive medical care from the intensive care unit;
  • Chronic kidney disease, stage 3 to 5;
  • Receiving ACEI/ARB group;

研究者

发起方
Bagheiat-allah University of Medical Sciences

相似试验